Mercy Medical Center   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Des Moines IA United States (1893)

Organization Overview

First Clinical Trial
2005
NCT00243984
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Anna Reinert | Mercy Medical Center

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma, Mucinous (Phase 2)

Appendiceal Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Communicable Diseases (Phase 2)

Cystadenocarcinoma (Phase 2)

Diabetes Mellitus, Type 2 (Phase 3)

Diverticulitis (Phase 4)

Fallopian Tube Neoplasms (Phase 2)

Fibrosis (Phase 4)

Hepatitis (Phase 4)

Hepatitis B (Phase 4)

Infections (Phase 2)

Liver Cirrhosis (Phase 4)

Liver Diseases (Phase 4)

Metabolic Syndrome (Phase 3)

Ovarian Neoplasms (Phase 2)

Pain, Postoperative (Phase 4)

Pseudomyxoma Peritonei (Phase 2)

Respiratory Tract Infections (Phase 2)

Syndrome (Phase 3)

Ureaplasma Infections (Phase 2)

Weight Loss (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 16